Office of Generic Drugs Accomplishments - 2015
At FDA’s Office of Generic Drugs (OGD) in the Center for Drug Evaluation and Research, 2015 was an exciting year. It marked the first full year of operation after expanding into a “Super Office” at FDA, which translates to more staffing to handle a growing workload—and greater ability to advance the quality and availability of cost saving generic drugs in the U.S.
Read more about OGD’s accomplishments in 2015 in the Annual Report and FDA Voice blog.
In addition, as part of the effort to align with stakeholders’ visions, OGD is holding a public meeting on May 20to solicit valuable feedback on regulatory science initiatives and help chart directions forward. You may also provide your thoughts and ideas to the public docket.
No hay comentarios:
Publicar un comentario